BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 26687425)

  • 21. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
    Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
    Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
    Styczynski J; Tridello G; Gil L; Ljungman P; Hoek J; Iacobelli S; Ward KN; Cordonnier C; Einsele H; Socie G; Milpied N; Veelken H; Chevallier P; Yakoub-Agha I; Maertens J; Blaise D; Cornelissen J; Michallet M; Daguindau E; Petersen E; Passweg J; Greinix H; Duarte RF; Kröger N; Dreger P; Mohty M; Nagler A; Cesaro S
    J Clin Oncol; 2016 Jul; 34(19):2212-20. PubMed ID: 27091716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
    Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
    Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in protein serum levels during stem cell transplantation.
    Metafuni E; Giammarco S; De Ritis DG; Rossi M; Corrente F; Piccirillo N; Bacigalupo AP; Sica S; Chiusolo P
    Eur J Clin Invest; 2017 Oct; 47(10):711-718. PubMed ID: 28796281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction.
    Mrazek F
    HLA; 2019 Dec; 94 Suppl 2():25-29. PubMed ID: 31729192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.
    Luft T; Benner A; Jodele S; Dandoy CE; Storb R; Gooley T; Sandmaier BM; Becker N; Radujkovic A; Dreger P; Penack O
    Lancet Haematol; 2017 Sep; 4(9):e414-e423. PubMed ID: 28733186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A biomarker panel for acute graft-versus-host disease.
    Paczesny S; Krijanovski OI; Braun TM; Choi SW; Clouthier SG; Kuick R; Misek DE; Cooke KR; Kitko CL; Weyand A; Bickley D; Jones D; Whitfield J; Reddy P; Levine JE; Hanash SM; Ferrara JL
    Blood; 2009 Jan; 113(2):273-8. PubMed ID: 18832652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Shin J; Dan K; Han D; Kim JW; Kim KK; Koh Y; Shin DY; Hong J; Yoon SS; Park S; Song SH; Kim I
    Blood Cells Mol Dis; 2019 Feb; 74():5-12. PubMed ID: 30344086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Murata M; Nakasone H; Kanda J; Nakane T; Furukawa T; Fukuda T; Mori T; Taniguchi S; Eto T; Ohashi K; Hino M; Inoue M; Ogawa H; Atsuta Y; Nagamura-Inoue T; Yabe H; Morishima Y; Sakamaki H; Suzuki R
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1183-9. PubMed ID: 23676716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Day 14 Endpoint for Acute GVHD Clinical Trials.
    Spyrou N; Akahoshi Y; Kowalyk S; Morales G; Beheshti R; Aguayo-Hiraldo P; Al Malki MM; Ayuk F; Bader P; Baez J; Capellini A; Choe H; DeFilipp Z; Eder M; Eng G; Etra A; Gleich S; Grupp SA; Hexner E; Hoepting M; Hogan WJ; Kasikis S; Katsivelos N; Khan A; Kitko CL; Kraus S; Kwon D; Merli P; Portelli J; Qayed M; Reshef R; Schechter T; Vasova I; Wölfl M; Wudhikarn K; Young R; Holler E; Chen YB; Nakamura R; Levine JE; Ferrara JLM
    Transplant Cell Ther; 2024 Apr; 30(4):421-432. PubMed ID: 38320730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
    MacMillan ML; Robin M; Harris AC; DeFor TE; Martin PJ; Alousi A; Ho VT; Bolaños-Meade J; Ferrara JL; Jones R; Arora M; Blazar BR; Holtan SG; Jacobsohn D; Pasquini M; Socie G; Antin JH; Levine JE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):761-7. PubMed ID: 25585275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific Metric.
    Rapoport Y; Freeman T; Koyama T; Engelhardt BG; Jagasia M; Savani BN; Tran U; Kassim AA
    Cornea; 2017 Feb; 36(2):258-263. PubMed ID: 28060078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
    Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.